Antibody responses to SARS-CoV-2 in patients with COVID-19

Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.

Abstract

We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • Antibody Formation / drug effects*
  • Antibody Formation / immunology
  • Antiviral Agents / therapeutic use
  • Betacoronavirus / genetics
  • Betacoronavirus / pathogenicity*
  • Coronavirus Infections / blood
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Female
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Male
  • Middle Aged
  • Pandemics / prevention & control
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulin G
  • Immunoglobulin M

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2